Systemic therapies for inflammatory eye disease: Past, Present and Future

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Denniston, Alastair K ^a   Dick, Andrew D ^b,c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

EVIDENCE BASED MEDICINE; EYE DISEASE; HUMAN; REVIEW; UVEITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; EVIDENCE-BASED MEDICINE; EYE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; UVEITIS;

EID: 84876664205     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-18     Document Type: Review

References (76)

1. Survey of expert practice and perceptions of the supporting clinical evidence for the management of uveitis-related cataract and cystoid macular oedema. Sreekantam S, Denniston AK, Murray PI, Ocul Immunol Inflamm 2011 19 353 357 10.3109/09273948.2011.592260 21823935
2. Methotrexate for ocular inflammatory diseases. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH, Ophthalmology 2009 116 2188 2198 10.1016/j.ophtha.2009.04.020 19748676
3. Cyclosporine for ocular inflammatory diseases. Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS, Ophthalmology 2010 117 576 584 10.1016/j.ophtha.2009.08.010 20031223
4. Azathioprine for ocular inflammatory diseases. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Suhler EB, Am J Ophthalmol 2009 148 500 509 10.1016/j.ajo.2009.05.008 19570522
5. Cyclophosphamide for ocular inflammatory diseases. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Foster CS, Ophthalmology 2010 117 356 365 10.1016/j.ophtha.2009.06.060 19969366
6. Mycophenolate mofetil therapy for inflammatory eye disease. Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP, Ophthalmology 2005 112 1472 1477 10.1016/j.ophtha.2005.02.020 16061096
7. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Sharma SM, Nestel AR, Lee RW, Dick AD, Ocul Immunol Inflamm 2009 17 403 414 10.3109/09273940903072443 20001261
8. Mycophenolate mofetil for the treatment of uveitis. Teoh SC, Hogan AC, Dick AD, Lee RW, Am J Ophthalmol 2008 146 752 760 760 10.1016/j.ajo.2008.03.004 18455143
9. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Durrani K, Zakka FR, Ahmed M, Memon M, Siddique SS, Foster CS, Surv Ophthalmol 2011 56 474 510 10.1016/j.survophthal.2011.05.003 22117884
10. Emerging drugs for uveitis. Larson T, Nussenblatt RB, Sen HN, Expert Opin Emerg Drugs 2011 16 309 322 10.1517/14728214.2011.537824 21210752
11. Savory J, Savory's Compendium of Domestic Medicine 1865 23611428
12. Effects of pituitary adrenocorticotrophic hormone (ACTH) therapy in ophthalmologic conditions. Gordon DM, McLEAN JM, J Am Med Assoc 1950 142 1271 1276 10.1001/jama.1950.02910340017005
13. Cyclophosphamide therapy of Behcet's disease. Buckley CE III, Gills JP Jr, J Allergy 1969 43 273 283 10.1016/0021-8707(69)90148-8 4238577
14. Cyclophosphamide therapy of peripheral uveitis. Buckley CE III, Gills JP Jr, Arch Intern Med 1969 124 29 35 10.1001/archinte.1969.00300170031006 5791483
15. Methotrexate treatment of uveal disease. Wong VG, Am J Med Sci 1966 251 239 241 5904740
16. Treatment of uveitis with azathioprine (Imuran). Newell FW, Krill AE, Trans Ophthalmol Soc U K 1967 87 499 511 5255241
17. Rescue therapy with mycophenolate mofetil in refractory uveitis. Kilmartin DJ, Forrester JV, Dick AD, Lancet 1998 352 35 36 10.1016/S0140- 6736(05)79515-5 9800750
18. Treatment of intraocular inflammatory disease with cyclosporin A. Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I, Lancet 1983 2 235 238 6135075
19. A clinical trial of FK506 in refractory uveitis. Mochizuki M, Masuda K, Sakane T, Ito K, Kogure M, Sugino N, Usui M, Mizushima Y, Ohno S, Inaba G, Am J Ophthalmol 1993 115 763 769 7685147
20. Cyclosporine therapy for uveitis: long-term followup. Nussenblatt RB, Palestine AG, Chan CC, J Ocul Pharmacol 1985 1 369 382 10.1089/jop.1985.1.369 3880086
21. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Nussenblatt RB, Palestine AG, Chan CC, Am J Ophthalmol 1983 96 275 282 6614105
22. Cyclosporin A: alterations of the cellular immune response in S-antigen-induced experimental autoimmune uveitis. Nussenblatt RB, Salinas-Carmona M, Waksman BH, Gery I, Int Arch Allergy Appl Immunol 1983 70 289 294 10.1159/000233339 6600715
23. Modulation of experimental autoimmune uveitis with cyclosporin A. Nussenblatt RB, Rodrigues MM, Salinas-Carmona MC, Gery I, Cevario S, Wacker W, Arch Ophthalmol 1982 100 1146 1149 10.1001/archopht.1982.01030040124022 6979993
24. Cyclosporin a, Inhibition of experimental autoimmune uveitis in Lewis rats. Nussenblatt RB, Rodrigues MM, Wacker WB, Cevario SJ, Salinas-Carmona MC, Gery I, J Clin Invest 1981 67 1228 1231 10.1172/JCI110138 7204576
25. Inhibition of experimental autoimmune uveoretinitis by mycophenolate mofetil, an inhibitor of purine metabolism. Chanaud NP III, Vistica BP, Eugui E, Nussenblatt RB, Allison AC, Gery I, Exp Eye Res 1995 61 429 434 10.1016/S0014-4835(05)80138-1 8549684
26. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Dick AD, Forrester JV, Liversidge J, Cope AP, Prog Retin Eye Res 2004 23 617 637 10.1016/j.preteyeres.2004.06.005 15388077
27. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Dick AD, McMenamin PG, Korner H, Scallon BJ, Ghrayeb J, Forrester JV, Sedgwick JD, Eur J Immunol 1996 26 1018 1025 10.1002/eji.1830260510 8647162
28. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J, J Autoimmun 1998 11 255 264 10.1006/jaut.1998.0197 9693974
29. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Murphy CC, Greiner K, Plskova J, Duncan L, Frost A, Isaacs JD, Rebello P, Waldmann H, Hale G, Forrester JV, Dick AD, Arch Ophthalmol 2004 122 845 851 10.1001/archopht.122.6. 845 15197059
30. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Arida A, Fragiadaki K, Giavri E, Sfikakis PP, Semin Arthritis Rheum 2011 41 61 70 10.1016/j.semarthrit.2010.09.002 21168186
31. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN, Lancet 2001 358 295 296 10.1016/S0140-6736(01)05497-6 11498218
32. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N, Ann Intern Med 2004 140 404 406 14996689
33. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD, Rosenbaum JT, Arch Ophthalmol 2009 127 819 822 19506209
34. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Bodaghi B, Bui QE, Wechsler B, Tran TH, Cassoux N, Le Thi HD, Chosidow O, Herson S, Piette JC, LeHoang P, Ann Rheum Dis 2005 64 962 964 10.1136/ard.2004.025882 15897316
35. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Okada AA, Goto H, Ohno S, Mochizuki M, Arch Ophthalmol 2012 130 592 598 10.1001/archophthalmol.2011.2698 22652845
36. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behcet's uveitis. Lee RW, Dick AD, Br J Ophthalmol 2010 94 269 270 10.1136/bjo.2009.176750 20215370
37. Biologics in the treatment of uveitis. Imrie FR, Dick AD, Curr Opin Ophthalmol 2007 18 481 486 10.1097/ICU.0b013e3282f03d42 18163000
38. Anti-TNF-alpha therapy for uveitis: Behcet and beyond. Murray PI, Sivaraj RR, Eye (Lond) 2005 19 831 833 10.1038/sj.eye.6701792
39. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Sfikakis PP, Curr Dir Autoimmun 2010 11 180 210 20173395
40. Carr DB, Jacox AK, Chapman CR, Acute pain management: operative or medical procedures and trauma. Clinical Practice Guideline. AHCPR Pub No 92-0032 Rockville (MD): Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services 1992 23517259
41. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Nussenblatt RB, Palestine AG, Chan CC, Stevens G Jr, Mellow SD, Green SB, Am J Ophthalmol 1991 112 138 146 1867297
42. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Lee RW, Greenwood R, Taylor H, Amer R, Biester S, Heissigerova J, Forrester JV, Dick AD, Ophthalmology 2012 119 1223 1230 10.1016/j.ophtha.2011.12.030 22381809
43. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Murphy CC, Greiner K, Plskova J, Duncan L, Frost NA, Forrester JV, Dick AD, Arch Ophthalmol 2005 123 634 641 10.1001/archopht.123.5.634 15883282
44. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ, Ocul Immunol Inflamm 2007 15 63 70 10.1080/09273940701299370 17558830
45. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE, Ophthalmology 2011 118 1916 1926 10.1016/j.ophtha.2011.07.027 21840602
46. Uveitis: a potentially blinding disease. Durrani OM, Meads CA, Murray PI, Ophthalmologica 2004 218 223 236 10.1159/000078612 15258410
47. Causes and frequency of blindness in patients with intraocular inflammatory disease. Rothova A, Suttorp-van Schulten MS, Frits TW, Kijlstra A, Br J Ophthalmol 1996 80 332 336 10.1136/bjo.80.4.332 8703885
48. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Gritz DC, Wong IG, Ophthalmology 2004 111 491 500 10.1016/j.ophtha.2003.06.014 15019324
49. Epidemiology of endogenous uveitis in south-western Finland. Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H, Tuominen J, Sillanpaa M, Acta Ophthalmol Scand 1995 73 345 349 8646582
50. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kacmaz RO, Pujari SS, Anzaar F, Foster CS, Helzlsouer KJ, Levy-Clarke GA, Nussenblatt RB, Liesegang T, Rosenbaum JT, Suhler EB, Ophthalmic Epidemiol 2008 15 47 55 10.1080/09286580701585892 18300089
51. Standardization of uveitis nomenclature for reporting clinical data, Results of the First International Workshop. Jabs DA, Nussenblatt RB, Rosenbaum JT, Am J Ophthalmol 2005 140 509 516 16196117
52. Structured Terminology Development of a Standardized Uveitis Nomenclature for Reporting Clinical Data. Trusko BE, Standardization of Uveitis Nomenclature (SUN) Working Group, IOVS 2011 52 RVO E-Abstract 4306
53. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Nussenblatt RB, Palestine AG, Chan CC, Roberge F, Ophthalmology 1985 92 467 471 4000641
54. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR, Am J Ophthalmol 2008 146 813 818 10.1016/j.ajo.2008.06.004 18687418
55. Scale for photographic grading of vitreous haze in uveitis. Davis JL, Madow B, Cornett J, Stratton R, Hess D, Porciatti V, Feuer WJ, Am J Ophthalmol 2010 150 637 641 10.1016/j.ajo.2010.05.036 20719302
56. Development of the 25-item National Eye Institute Visual Function Questionnaire. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD, Arch Ophthalmol 2001 119 1050 1058 10.1001/archopht.119.7.1050 11448327
57. Development of a questionnaire for measurement of vision-related quality of life. Frost NA, Sparrow JM, Durant JS, Donovan JL, Peters TJ, Brookes ST, Ophthalmic Epidemiol 1998 5 185 210 10.1076/opep.5.4.185.4191 9894804
58. Visual functioning and general health status in patients with uveitis. Schiffman RM, Jacobsen G, Whitcup SM, Arch Ophthalmol 2001 119 841 849 10.1001/archopht.119.6.841 11405835
59. Quality of life and visual function in patients with intermediate uveitis. Murphy CC, Hughes EH, Frost NA, Dick AD, Br J Ophthalmol 2005 89 1161 1165 10.1136/bjo.2005.067421 16113373
60. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Murphy CC, Greiner K, Plskova J, Frost NA, Forrester JV, Dick AD, Br J Ophthalmol 2007 91 154 156 10.1136/bjo.2006. 105528 16973657
61. Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial. Frick KD, Drye LT, Kempen JH, Dunn JP, Holland GN, Latkany P, Rao NA, Sen HN, Sugar EA, Thorne JE, Wang RC, Holbrook JT, Invest Ophthalmol Vis Sci 2012 53 1169 1176 10.1167/iovs.11-8259 22247489
62. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L, BMJ 1992 305 160 164 10.1136/bmj.305.6846.160 1285753
63. EuroQol - a new facility for the measurement of health-related quality of life. Euroqol group, Health Policy 1990 16 199 208 10109801
64. Cystic fibrosis. O'Sullivan BP, Freedman SD, Lancet 2009 373 1891 1904 10.1016/S0140-6736(09)60327-5 19403164
65. Analysis of 14 cystic fibrosis mutations in five south European populations. Nunes V, Gasparini P, Novelli G, Gaona A, Bonizzato A, Sangiuolo F, Balassopoulou A, Gimenez FJ, Dognini M, Ravnik-Glavac M, Hum Genet 1991 87 737 738 1937479
66. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS, N Engl J Med 2011 365 1663 1672 10.1056/NEJMoa1105185 22047557
67. Non-syndromic retinal ciliopathies: translating gene discovery into therapy. Estrada-Cuzcano A, Roepman R, Cremers FP, den Hollander AI, Mans DA, Hum Mol Genet 2012 21 R1 111-24 22843501
68. Mutations of the BRAF gene in human cancer. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA, Nature 2002 417 949 954 10.1038/nature00766 12068308
69. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G, Proc Natl Acad Sci U S A 2008 105 3041 3046 10.1073/pnas.0711741105 18287029
70. Inhibition of mutated, activated BRAF in metastatic melanoma. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB, N Engl J Med 2010 363 809 819 10.1056/NEJMoa1002011 20818844
71. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A, N Engl J Med 2012 366 707 714 10.1056/NEJMoa1112302 22356324
72. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, N Engl J Med 2011 364 2507 2516 10.1056/NEJMoa1103782 21639808
73. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, Androudi S, Ophthalmology 2013 120 4 777 87 10.1016/j.ophtha.2012.09.040 23290985
74. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ, Clin Pharmacol Ther 2009 86 97 100 10.1038/clpt.2009.68 19440188
75. Adaptive clinical trials: the promise and the caution. Berry DA, J Clin Oncol 2011 29 606 609 10.1200/JCO.2010.32.2685 21172875
76. Adaptive clinical trials in oncology. Berry DA, Nat Rev Clin Oncol 2012 9 199 207